Cytokinetics Inc EVP of Research and Development Fady Ibraham filed a Form 4 on November 3, 2026, disclosing the exercise of 3,500 stock options and the same-day sale of 3,500 shares of common stock under a Rule 10b5-1 plan.

Key Highlights

  • Option exercise: Ibraham exercised 3,500 non-qualified stock options on November 3, 2026, at an exercise price of $7.80 per share, acquiring 3,500 shares of common stock.
  • Shares sold: 3,500 shares of common stock were disposed of on November 3, 2026, at a price of $62.93 per share.
  • Remaining beneficial ownership: Following the transactions, Ibraham directly held 153,902 shares of common stock.
  • Remaining options: Ibraham retains 12,886 non-qualified stock options with an exercise price of $7.80, expiring February 27, 2028.
  • Rule 10b5-1 plan: The filing indicates the transactions were made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).

Cytokinetics EVP Ibraham Reports Option Exercise and Stock Sale on November 3, 2026

According to the Form 4 filed with the SEC, Fady Ibraham, identified as Executive Vice President of Research and Development at Cytokinetics Inc (NASDAQ:CYTK), reported two transactions in the company's common stock on November 3, 2026. Both transactions were executed under a written plan consistent with Rule 10b5-1(c), as indicated by a checkbox on the filing.

The first transaction, coded "M," reflects the exercise of 3,500 non-qualified stock options at a conversion price of $7.80 per share, resulting in the acquisition of 3,500 shares of common stock. These options had an exercisable date of March 27, 2018, and an expiration date of February 27, 2028, the filing states. The price of the derivative security in connection with the exercise is listed as $0. Following the exercise, Ibraham's beneficial ownership in common stock stood at 157,402 shares before the sale was recorded.

The second transaction, coded "S," reflects the disposal of 3,500 shares of common stock at $62.93 per share. After this sale, Ibraham's direct beneficial ownership in common stock totaled 153,902 shares, according to the filing. His remaining directly held non-qualified stock options numbered 12,886, all carrying the same $7.80 exercise price and February 27, 2028, expiration date. The filing was signed by John O. Faurescu as attorney-in-fact for Dr. Malik on November 3, 2026.

What Was Disclosed

The filing reports an option exercise of 3,500 shares at $7.80 and an equal same-day sale at $62.93 by Cytokinetics EVP Fady Ibraham, both conducted under a Rule 10b5-1 plan, leaving him with 153,902 shares of common stock directly held.